Water under the bridge: Postmarketing concerns as related to pediatric populations

Drug Information Journal

Volumn 30, Issue 4, 1996, Pages 1163-1171

  Sylvestri, Mario F ^a,b  

^a SANOFI   (France)

^b Hlth Econ and Outcomes Management   (United States)

Author keywords

Clinical trials; Disease and outcomes management; Longitudinal studies; New drug applications; Pediatric labeling; Postmarketing surveillance; Prospective pharmacoepidemiology studies

Indexed keywords

NEW DRUG;

CHILD; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HUMAN; INFANT; MEDICAL ETHICS; NEWBORN; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0029852060     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000435     Document Type: Review

References (17)

1. Wierenga DE, Beary JF III. The drug development and approval process. Office of Research and Development, Pharmaceutical Research and Manufacturers of America. January 1995.
2. Members of the ASCPT Pharmacoepidemiology Section. Notes of the American Society for Clinical Pharmacology and Therapeutics. Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. November 1990.
3. Pharmaceutical Manufacturers Association. New medicines in development for children. Fall 1990: 1-12.
4. Pharmaceutical Research and Manufacturers of America. New medicines in development for AIDS. November 1994:1-12.
5. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995; 95(2):286-294.
6. Kauffman RE. Drug trials in children: ethical, legal, and practical issues. J Clin Pharmacol. 1994;34: 296-299.
7. Pediatric use labeling. FDA Medical Bulletin. August 1995;3.
8. Wilson JT, Kearns GL, Murphy D, Yaffe SJ. Pediatric labelling requirements: implications for pharmacokinetic studies. Clin Pharmacokinet. 1994;26(4): 308-325.
9. Twomey JG, Jr. Investigating pediatric HIV research ethics in the field. West J of Nurs Res. 1994;16(4): 404-413.
10. Jensen PS, Vitiello B, Leonard H, Laughren TP. Design and methodology issues for clinical treatment trials in children and adolescents. Psychopharmacol Bul. 1994;30(1):3-8
11. Bruppacher R, Gelzer J. Identifying, evaluating, and quantifying adverse drug reactions in children: opportunities and obstacles for the manufacturer. Bratisl Lek Listy. 1991;92(11):549-553.
12. Department of Health and Human Services. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, DC: Government Printing Office. 1991; DHHS Publication No. [PHS]911-50213.
13. National Cholesterol Education Program (NCEP). Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89:495-501.
14. King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. J Pediatric Infec Dis. 1994;13:394-107.
15. Gal P, Reed MD, Nahata MC. Recent advances in pediatrics. Ann Pharmacother. 1995;29:66-70.
16. Crosson FJ. Why outcomes measurement must be the basis for the development of clinical guidelines. Man Care Quart. 1995;3(2):6-11.
17. Langfitt TN. Outcomes management. Surg Neurol. 1991;35:111.